Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to -$19.8 million.

  • Artiva Biotherapeutics' Free Cash Flow fell 69.14% to -$19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.9 million, marking a year-over-year decrease of 50.95%. This contributed to the annual value of -$55.7 million for FY2024, which is 9.84% down from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Free Cash Flow is -$19.8 million, which was up 16.33% from -$23.7 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Free Cash Flow high stood at -$10.9 million for Q3 2023, and its period low was -$23.7 million during Q2 2025.
  • Its 3-year average for Free Cash Flow is -$15.8 million, with a median of -$14.7 million in 2024.
  • Data for Artiva Biotherapeutics' Free Cash Flow shows a maximum YoY crashed of 69.14% (in 2025) over the last 5 years.
  • Over the past 3 years, Artiva Biotherapeutics' Free Cash Flow (Quarterly) stood at -$11.3 million in 2023, then slumped by 30.09% to -$14.7 million in 2024, then crashed by 69.14% to -$19.8 million in 2025.
  • Its last three reported values are -$19.8 million in Q3 2025, -$23.7 million for Q2 2025, and -$20.7 million during Q1 2025.